Skip to main content
. 2011 Apr 29;6(4):e19330. doi: 10.1371/journal.pone.0019330

Figure 3. Prevalence of melanoma-reactive antibodies derived from melanoma patient B cell cultures is reduced in advanced disease stages.

Figure 3

(A) Comparison of mean antibody culture reactivity to A-375 cells (fold increase relative to negative control human IgG antibody) for patients with localized (non-metastatic, n = 9) and metastatic (n = 12) disease, P<0.0001. (B) Mean reactivity to A-375 cells (fold increase relative to negative control antibody) of cultures from patients with stage II (n = 8), III (n = 6) and IV (n = 6) melanoma. Antibody reactivity was determined using a cell-based ELISA. Fold increase values in panels A and B were determined relative to the mean absorbance to a negative control human IgG antibody. ***P<0.001 and ** P =  0.001 to 0.01. Error bars in figures represent 95% confidence intervals.